[Articles] Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Journal content Created on 06 Jun 2026 The Lancet

Published in

The Lancet, The Lancet (Reed Elsevier)

Content

There is no additional content. Please click on the source link to view more information.

Harpreet S Bajaj, Michelle Welch, Parag Shah, Eduardo Luna, Fatima-Zahra Jaouimaa, Bing Liu, Rong Liu, Yanyun Chen, Hiren Patel, Amy Bartee

Attention!

On Life Science Network, we import abstract of articles published in the most popular journals. In addition, members of our network often upload full article pdfs of their research.

To access all content shared in our network and the source link, please sign up for an account. If you already have an account, sign in, or connect with LinkedIn, Google.

Stats

Recommendations n/a n/a positive of 0 vote(s)
Views 190
Comments 0

Comments

There are no comments yet.

Published in

Content

Attention!

Stats

Recommended by

Post a comment

Comments